Two directors at Opus Genetics, Inc. (IRD) divested a significant number of shares on May 18, 2026, totaling approximately $14.79 million. The Fighting Blindness Retinal Degeneration Fund Foundation sold 1,700,000 shares at $4.35 per share, realizing $7.39 million. Concurrently, Fighting Blindness, Inc. Foundation also sold 1,700,000 shares at the same price point, generating another $7.39 million.
These transactions represent a notable capital outflow from entities closely associated with the company's leadership. While insider selling can be attributed to various personal financial strategies, such as portfolio diversification or liquidity needs, a coordinated sale by multiple insiders can sometimes signal a shift in their outlook on the company's prospects.
The sales occurred amidst a period of recent insider activity, including smaller sales by other executives earlier in April. Investors often monitor insider transactions for insights into executive confidence in their company's performance and future valuation.